10-Q: Kintara Therapeutics Reports Q3 2024 Results, Announces Merger with TuHURA Biosciences

Kintara Therapeutics announced its Q3 2024 financial results, highlighted by a merger agreement with TuHURA Biosciences and the restart of the REM-001 clinical trial, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.

Summary

• Kintara Therapeutics reported a net loss of $5.996 million for the nine months ended March 31, 2024, and a negative cash flow from operations of $5.734 million.
• The company's cash and cash equivalents stood at $6.351 million as of March 31, 2024, with an accumulated deficit of $157.550 million.
• Kintara is a clinical-stage company and has not generated any revenue to date.
• The company has suspended the development of VAL-083 after it failed to perform better than current standards of care in glioblastoma.
• Kintara has re-initiated its REM-001 program for cutaneous metastatic breast cancer (CMBC) following a $2 million grant from the National Institutes of Health (NIH).
• The company entered into a merger agreement with TuHURA Biosciences, expected to close in the third calendar quarter of 2024, subject to stockholder and regulatory approval.
• Existing Kintara stockholders will receive contingent value rights (CVR) entitling them to shares upon achieving certain enrollment milestones in the REM-001 clinical trial.
• The company has raised $10.471 million through an at-the-market (ATM) facility and $105 thousand through a stock purchase agreement during the nine months ended March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern within one year from the date of filing these financial statements.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with significant financial challenges and the termination of a key program, but also includes positive developments such as the re-initiation of the REM-001 program and a merger agreement. The overall sentiment is negative due to the going concern issues and financial losses.

Positives

• The company has re-initiated the REM-001 program for CMBC, which has shown promising results in previous studies.
• Kintara secured a $2 million grant from the NIH to support the REM-001 clinical trial.
• The merger with TuHURA Biosciences could provide a strategic path forward for the company.
• The company has raised $10.576 million through equity financing during the nine months ended March 31, 2024.

Negatives

• The company reported a significant net loss of $5.996 million for the nine months ended March 31, 2024.
• Kintara has an accumulated deficit of $157.550 million.
• The company has terminated the development of VAL-083 after it failed to meet expectations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is not currently in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Risks

• The company's ability to continue as a going concern is in doubt due to its financial losses and lack of revenue.
• The company may not be able to raise sufficient additional capital to fund its operations.
• The proposed merger with TuHURA Biosciences is subject to stockholder and regulatory approval and may not be completed.
• The company's common stock may be delisted from The Nasdaq Capital Market if it does not regain compliance with the minimum bid price requirement.
• The company's clinical trials and research and development programs may be delayed or reduced if sufficient funding is not secured.

Future Outlook

The company is focused on completing the merger with TuHURA Biosciences and advancing the REM-001 clinical trial. The company will require additional funding to maintain its operations and is exploring various financing alternatives. The company's ability to continue as a going concern is dependent on securing additional funding or completing the merger.

Management Comments

• Management is pursuing various financing alternatives to fund the company's operations.
• Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, including debt, entering into strategic partnership arrangements, and/or pursuing additional strategic transactions.
• Management believes that REM-001 Therapy holds promise as a treatment to locally eliminate, or slow the growth of, treated cutaneous cancerous tumors.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on developing novel cancer therapies. The termination of VAL-083 development reflects the high risk and uncertainty associated with drug development. The re-initiation of the REM-001 program and the merger with TuHURA Biosciences indicate a strategic shift towards a more focused approach. The company's financial challenges are not uncommon for clinical-stage biopharmaceutical companies that are dependent on external funding.

Comparison to Industry Standards

• Kintara's financial situation is not uncommon for clinical-stage biotech companies, many of which operate at a loss while developing their products.
• The termination of the VAL-083 program is a common occurrence in the industry, where clinical trials often fail to meet expectations.
• The company's focus on REM-001, a photodynamic therapy, is a niche area within oncology, with limited direct comparables.
• The merger with TuHURA Biosciences is a strategic move that is not uncommon for companies facing financial challenges, similar to the merger of Mustang Bio and Fortress Biotech.
• The company's reliance on grants and equity financing is typical for companies at this stage, similar to companies like Agenus and OncoSec Medical.

Related Party Transactions

• The company has related party transactions with Valent Technologies, LLC, including royalty agreements and dividends on Series A Preferred Stock.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and potential delisting.
• Employees may be affected by potential cost-cutting measures or changes in the company's direction.
• Patients may benefit from the development of REM-001, but the program's future is dependent on securing additional funding.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• Complete the merger with TuHURA Biosciences.
• Advance the REM-001 clinical trial.
• Secure additional funding through various financing alternatives.
• Regain compliance with Nasdaq's minimum bid price requirement.

Key Dates

Keywords

Kintara Therapeutics, TuHURA Biosciences, REM-001, VAL-083, merger, clinical trial, cutaneous metastatic breast cancer, photodynamic therapy, financial results, going concern, capital raise